Clinical trials: Depressive; Behavioral Disorder
Depressive Disorder, Depression
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- NCT01727726
- Testing
- Brexpiprazole, Seroquel XR
- Where
- 76 sites in United States, Canada and 5 more
- Volunteers
- 2,182 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Unipolar Depression, Major Depressive Disorder (MDD)
Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression
The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach.
- Conditions
- Unipolar Depression, Major Depressive Disorder (MDD), Depression
- Trial name
- EMC2FR (NCT06860165)
- Where
- 2 sites in France
- Volunteers
- 98 people
- Sponsor
- Emobot
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly…
- Trial name
- ZEPHIR (NCT00319709)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Finland and 3 more
- Volunteers
- 288 people
- Sponsor
- Sanofi
Major Depressive Disorder
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®.
- Trial name
- NCT01369030
- Testing
- Deplin®
- Where
- 2 sites in United States
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01377194
- Testing
- Levomilnacipran ER
- Where
- 51 sites in United States, Canada
- Volunteers
- 568 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in…
- Trial name
- CES-MDD (NCT05384041)
- Testing
- Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- Fisher Wallace Laboratories
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969709
- Testing
- Levomilnacipran ER
- Where
- 38 sites in United States
- Volunteers
- 724 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Depression
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Pyxis (NCT01360645)
- Testing
- OPC-34712 + ADT
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 826 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Symptoms, Urinary Incontinence
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and urinary incontinence in women who delivered a healthy…
- Trial name
- NCT07413692
- Testing
- EXOMIND (BTL-699-2) ActiveTreatment, EMSELLA (HPM-6000UF) ActiveTreatment
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- BTL Industries Ltd.
Major Depressive Disorder
Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
The main purpose of this study is to evaluate the effect of desvenlafaxine administered as DVS SR on the pharmacokinetics of midazolam in healthy male and female subjects.
- Trial name
- NCT00952653
- Testing
- Desvenlafaxine Succinate Sustained Release, Midazolam
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD.
- Trial name
- EXTEND (NCT06605105)
- Testing
- CYB003
- Where
- 49 sites in United States, Australia and 3 more
- Volunteers
- 468 people
- Sponsor
- Cybin IRL Limited
Major Depressive Disorder
AZD6765 Severe Major Depressive Disorder (MDD) IV
The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication.
- Trial name
- NCT00781742
- Testing
- AZD6765
- Where
- 27 sites in United States
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Depressive Episode, Bipolar 1 Depression
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
A clinical study to test the effectiveness of an investigational drug to treat people that have major depressive episodes when they have Bipolar 1 Depression
- Trial name
- NCT03543410
- Testing
- SEP-4199 200 mg, SEP-4199 400 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 344 people
- Sponsor
- Sumitomo Pharma America, Inc.
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder
The purpose of this study is to determine whether RX-10100 are effective in the treatment of Major Depressive Disorder (MDD).
- Trial name
- MDD (NCT01273376)
- Testing
- RX-10100
- Where
- 44 sites in United States
- Volunteers
- 314 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Major Depressive Disorder
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
- Trial name
- NCT00854100
- Testing
- Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
- Where
- 41 sites in United States
- Volunteers
- 231 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment…
- Trial name
- JUNIPER (NCT05536414)
- Testing
- Centanafadine, Escitalopram
- Where
- 62 sites in United States
- Volunteers
- 337 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Symptoms, Anxiety Disorders
Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study
Therapies delivered via technology have been developed to improve accessibility, however, there is limited research regarding messaging therapy in particular, and none that we know of utilizing a longitudinal effectiveness…
- Trial name
- NCT03699488
- Testing
- psychotherapy via asynchronous message
- Volunteers
- 12,980 people
- Sponsor
- Talkspace